Do you offer local consolidative therapy for patients with polymetastatic driver mutation-positive NSCLC who respond well to targeted therapy?

Topics: Radiation Oncology • Thoracic Malignancies • Medical Oncology • MD Anderson • NCI-CCC Tumor Board Question • Non-small cell lung cancer • NCI-CCC Thoracic Tumor Board Question

If so, when and to what extent?

Answer from: Medical Oncologist at Academic Institution

This is a great question. In phase II prospective study, Gomez and colleagues (Gomez et al., PMID 31067138) demonstrated a PFS and OS benefit with local consolidative therapy in patients whose disease did not progress after first-line systemic therapy. In my opinion, local consolidation therapy to o...

Comments

Radiation Oncologist at National Cancer Institute
The question was about polymetastatic, driver-muta...

Related Questions